基因组分析揭示了P21激活激酶的变化与多种癌症类型的患者存活率之间的反向相关性
Jessie M Vo1, Linh M La1, Ananda V Anderson1
1Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, USA.
Physiological reports
|January 5, 2025
概括
激活P21激活激酶 (PAKs) 的遗传变化与几种癌症患者的生存率降低有关. 作为预测生物标志物和治疗点,PAKs显示出前景,特别是在转移性疾病中.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 由于缺乏可靠的生物标志物和有效的治疗方法,转移性癌症存在重大治疗挑战.
- P21激活激酶 (PAKs) 涉及癌症进展,但它们作为预测标记物和治疗点的作用仍未得到充分研究.
- 在PAK异型中发生的遗传变化可能与患者存活率下降有关.
研究的目的:
- 调查PAK基因中的遗传变化与患者整体存活率之间的关联.
- 探索PAK异型的潜力,作为转移的预测生物标志物.
- 评估PAK作为各种癌症类型的治疗点.
主要方法:
- 利用了来自cBioPortal的癌症基因组学数据.
- 分析了多个随机的,多中心的第三期临床试验数据集.
- 检查了与生存结果相关的PAK基因的基因变异和表达水平.
主要成果:
- 在乳腺癌,前列腺癌,胰腺癌和肺癌中发现了PAK基因的显著基因变异.
- 增加PAK表达与前列腺癌和乳腺癌患者的生存率较差相关.
- 在胰腺癌和肺癌中观察到PAK变化的生存率较低的趋势,尽管在统计学上并不显著.
结论:
- 帕克是重要的潜在生物标志物和治疗点,特别是在转移性癌症中.
- 针对PAK相关途径的有针对性的干预可以改善患者的治疗结果.
- 帕克可以作为癌症诊断,监测和个性化治疗策略的可靠生物标志物.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.1K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.3K
相关概念视频
Cancer Survival Analysis
290
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
290
Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.2K
Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
M-Cdk Drives Transition Into Mitosis
5.4K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K
